Does the COVID-19 rebound risk change with or without Paxlovid treatment?

If you've taken Paxlovid, you've probably worried about 'rebound'—that frustrating return of COVID-19 symptoms after you start feeling better. Doctors and patients have been asking whether the drug itself plays a role. To find out, researchers ran gold-standard clinical trials, giving some people Paxlovid and others a placebo, then watching to see what happened. The trials were conducted at sites in the United States and internationally. The study was designed to be rigorous, using a randomized, double-blind method so neither patients nor doctors knew who was getting the real drug. This is the kind of setup that can give us clear answers. However, the specific results from these trials—like how many people rebounded in each group or whether there was a difference—are not yet publicly reported. We also don't know key details about the people in the study or if there were any safety concerns. So, while this research tackles the right question head-on, we're still waiting for the crucial numbers that tell the full story.